BioSpace

FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns

After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year.

By BioSpace

1 min read
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights